// App-Quantinova.ai

10537 : ADVL1522: A phase 2 study of IMGN901 (lorvotuzumab mertansine; IND# 126953, NSC# 783609) in children with relapsed or refractory Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST), and synovial sarcoma: A Children's Oncology Group study.

Researchers

Presenter

  • James I. Geller

Principal Investigators

  • Joseph Gerald Pressey

  • Malcolm A. Smith

  • Rachel A. Kudgus

  • Renee Schoon

  • Renee M. McGovern

  • Mariana Cajaiba

  • Joel M. Reid

  • David Hall

  • Donald A. Barkauskas

  • Jeffrey Dome

  • Elizabeth Fox

  • Brenda Weigel

Medical Centers

  • Cincinnati Children's Hospital Medical Center, Cincinnati, OH

  • Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

  • Mayo Clinic, Rochester, MN

  • Department of Oncology, Mayo Clinic, Rochester, MN

  • Lurie Children's Hospital, Chicago, IL

  • Children's Oncology Group, Monrovia, CA

  • Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA

  • Children's National Health System, Washington, DC

  • University of Philadelphia, Philadelphia, PA

  • University of Minnesota, Minneapolis, MN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Lorvotuzumab mertansine

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • BIWI-1

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved